<DOC>
	<DOCNO>NCT03010956</DOCNO>
	<brief_summary>Arterial stiffness associate increase risk cardiovascular disease . Moreover , integrity endothelial glycocalyx play vital role vascular permeability , inflammation elasticity . The purpose study investigate change arterial stiffness endothelial glycocalyx thickness patient poorly control diabetes mellitus type 1 type 2 glycemic control optimal medication .</brief_summary>
	<brief_title>Changes Arterial Stiffness Endothelial Glycocalyx Patients With Poorly Controlled Diabetes Mellitus Type 1 Type 2 After Optimization Antidiabetic Medication .</brief_title>
	<detailed_description>The investigator study two group match age sex : 30 patient uncontrolled type 1 diabetes 30 patient uncontrolled type 2 diabetes . Individuals treat statin , beta-blockers , ACE inhibitor , sartans , hormonal preparation , drug interfere function platelet hemostasis . Furthermore , heart failure , nephropathy retinopathy . 10 people remain uncontrolled expiration 3 month modification antidiabetic medication use control group . At 0 , 3 , 6 12 month investigator measure : 1 . Carotid-femoral pulse wave velocity ( PWV , m/sec ) augmentation index ( AI % ) method arteriography ( Arteriograph , TensioMed ) Complior ( SP ALAM ) . 2 . Perfused boundary region ( PBR , micrometer ) sublingual arterial microvessels ( range 5-25 micrometer ) use Sideview Darkfield imaging ( Microscan , Glycocheck ) . Increased PBR consider accurate non invasive index reduce endothelial glucocalyx thickness . 3 . Flow mediate dilatation ( FMD ) brachial artery . 4 . Determination follow parameter blood : glucose , insulin , free fatty acid , triglyceride , glycerol , C-reactive protein ( CRP ) , transform growth factor-b ( TGF-b ) , Lipoprotein-Associated Phospholipase A2 ( LP-LPA2 ) , tumor necrosis factor-a ( TNF-a ) , IL6 IL10 ( interleukin ) , propeptide type I procollagen ( PIP ) , propeptide procollagen type III ( PIIINP ) , matrix metallopeptidases 9 2 ( MMP ) , macrophage-colony stimulating factor ( MCSF ) , growth differentiation factor-15 ( GDF-15 ) , N-terminal pro b-type natriuretic peptide ( NT-proBNP ) galectin-3 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Patients uncontrolled diabetes mellitus valvular heart disease congestive heart failure peripheral vascular disease liver kidney failure history alcohol drug abuse treatment statin , beta blocker , ACE inhibitor sartans</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Arterial stiffness</keyword>
	<keyword>Endothelial glycocalyx</keyword>
	<keyword>Coronary flow reserve</keyword>
</DOC>